Stock Analysis
Beam Therapeutics Inc. (BEAM) Stock Analysis
Beam Therapeutics Inc. (BEAM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Beam Therapeutics Inc. (BEAM) currently has an AIQ Score of 32/100, indicating a bearish setup. Risk is the strongest factor at 36/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BEAM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $23.99 |
| AIQ Score | 32/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.99B |
| P/E Ratio | -8.82 |
| Forward P/E | — |
| EPS | -$1.18 |
| Revenue TTM | $490K |
| Dividend Yield | 0.00% |
| Beta | 2.21 |
| Volume | 1.19M |
| 52-week range | $19.57-$38.26 |
| RSI 14 | 28.23 |
| 50-Day SMA | $28.61 |
| 200-Day SMA | $28.60 |
| Analyst Price Target | $59.50 |
| Next Earnings | Nov 3, 2026 |
BEAM
OverviewBEAM Stock Analysis Summary
Beam Therapeutics Inc. (BEAM) currently has an AIQ Score of 32/100, indicating a bearish setup. Risk resilience is the strongest factor at 36/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, BEAM has AIQ Score of 32/100 with Risk resilience base of 36/100 and fading Momentum at 23/100. Wait for component alignment before adding exposure.
Healthcare · -1.56% stock move · BEAM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BEAM Bullish or Bearish Right Now?
BEAM currently has a bearish overall setup. Risk Resilience is the strongest factor at 36/100, while Momentum is weakest at 23/100. The current evidence suggests a defensive setup.
- - Analyst target implies +148.02% upside from the latest quote.
- - Value is the current constraint at 34/100.
- - Momentum is weak at 23/100.
- - Risk Resilience is weak at 36/100.
- - Price is -16.12% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 9).
Current Consensus
BEAM's Technical Analysis Consensus is currently Strong Sell, with 9 buy, 1 neutral, and 35 sell votes. BEAM's 14-day RSI is 28.23, which places the stock in an oversold momentum range. BEAM's beta is 2.21, indicating greater market sensitivity than the broad market.
What Changed in BEAM?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the BEAM Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BEAM Decision Framework
Public evidence layers, setup checks, and risk context for Beam Therapeutics Inc..
Beam Therapeutics Inc. (BEAM) Stock Analysis
Beam Therapeutics Inc. has an AIQ Score of 32/100 in a Defensive regime. Risk is strongest at 36/100. Beta is 2.21, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BEAM is in a Defensive AIQ regime with score 32/100. |
| Signal Conflict | The primary conflict is that risk leads at 36/100 while momentum lags at 23/100. |
| Factor Evidence | Momentum 23/100 · Value 34/100 · Quality 35/100 · Risk 36/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 36/100.
Momentum is 23/100 and RSI (14) is 28.2.
BEAM is in a Defensive regime at 32/100.
Risk factor is 36/100 with beta 2.21 and annual volatility 75.17%.
Current conflict: risk leads at 36/100 while momentum lags at 23/100.
BEAM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BEAM Fundamentals
BEAM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BEAM Technical Analysis
BEAM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BEAM Stock Catalysts
Track BEAM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BEAM Dividend Analysis
BEAM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BEAM Financial Data
BEAM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BEAM Risk Analysis
BEAM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BEAM Stock News
BEAM stock news, market tone, recent headlines, and catalyst context.
BEAM vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: BEAM · CRSP · DNLI · DTIL · EDIT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BEAM Current stock | 32/100 | 34/100 | 23/100 | 36/100 | 0.56 | 75.17% | Current |
| CRSP CRISPR Therapeutics | 29/100 | 34/100 | 22/100 | 41/100 | 0.23 | 60.11% | BEAM vs CRSP |
| DNLI Denali Therapeutics | 37/100 | 34/100 | 31/100 | 70/100 | 0.86 | 56.56% | BEAM vs DNLI |
| DTIL Precision BioSciences | 49/100 | 60/100 | 31/100 | 51/100 | 0.8 | 72.10% | BEAM vs DTIL |
| EDIT Editas Medicine | 41/100 | 34/100 | 38/100 | 39/100 | 0.44 | 85.13% | BEAM vs EDIT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BEAM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BEAM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BEAM Stock FAQ
What is BEAM stock price today?
Beam Therapeutics Inc.'s current stock price is $23.99. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BEAM bullish or bearish right now?
BEAM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BEAM's market cap?
BEAM's market cap is $2.99B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BEAM's current P/E ratio?
BEAM's current P/E ratio is -8.82 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BEAM's RSI?
BEAM's 14-day RSI is 28.23 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BEAM above its 50-day and 200-day moving averages?
BEAM is -16.14% from its 50-day SMA and -16.12% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BEAM's next earnings date?
BEAM's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BEAM pay a dividend?
BEAM's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.